GALE Key Stats
- A Journey To Add Biotech To The Portfolio May 18
- GALENA BIOPHARMA, INC. Financials May 17
- GALENA BIOPHARMA, INC. Files SEC form 8-K, Changes in Registrant's Certifying Ac... May 16
- Galena Targets Cancer Pain Market May 15
- Alexza Pharmaceuticals: A Teva Partnership Of Immense Meaning May 15
- Galena Biopharma: Stock First, Science Second? May 13
- VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results GlobeNewswire May 9
- GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial C... May 9
- Galena Biopharma's Abstral serves as model for TIRF REMS program May 9
- Galena Biopharma Poster Presentation at the American Pain Society 32nd Annual Sc... May 9
GALE Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Galena Biopharma is up 51.88% over the last year vs S&P 500 Total Return up 30.71%, AVEO Pharmaceuticals down 73.98%, and Achillion Pharmaceuticals up 19.54%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for GALE
Pro Report PDF for GALE
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download GALE Pro Report PDF
Pro Strategies Featuring GALE
Did Galena Biopharma make it into our Pro Portfolio Strategies?